Pharma Excipients Maker Sees Strong Investor Response Before Final Bidding Window Shuts at 5 PM
Sudeep Pharma’s initial public offering is set to close successfully today, November 25, 2025, after garnering strong investor interest throughout the subscription period. The IPO, which opened on November 21, has already crossed the 5-times subscription mark, signaling robust demand for the company’s shares.
As of November 24, the IPO showed a subscription of over 5.13 times, with the retail category particularly driving interest. Retail investors subscribed to 5.02 times their allocated amount, demonstrating confidence in the pharmaceutical excipients manufacturer.
About the Offering
Sudeep Pharma is offering a total of 1,50,92,750 equity shares worth ₹895 crores. The issue comprises a fresh issue of ₹95 crore and an offer for sale of ₹800 crore from existing shareholders. The price band is set between ₹563 and ₹593 per share, with a minimum investment of approximately ₹14,825 for retail investors.
Investors can bid for a minimum of 25 shares and multiples thereof. The bidding window closes today at 5 PM IST.
Possible Gains
Shares that are not yet officially listed are selling unofficially at ₹679. That’s about 14.5% more than the highest price the company is asking. Based on this, many think the shares could open around ₹714 when they start trading. This would mean people could make about 20% profit right away.
Who is Sudeep Pharma?
Sudeep Pharma makes ingredients used in making medicines and health products. Last year, the company earned ₹501.9 crore and made very good profits. The company runs six factories across India. These factories together can make 50,000 tonnes of products every year. They use modern machines and follow world-class standards. The company makes over 200 different products and sells them to more than 100 countries. It has 704 people working for it.
The company has its own research team with laboratories where it tests and develops new products. They work mainly on making mineral-based ingredients and special health formulations. The company has two main businesses. One makes mineral ingredients like calcium, zinc, and iron used in medicines and food. The other business, through a separate company called SNPL, makes special vitamin mixes and advanced medicine formats.
What’s Next
The basis of allotment will be finalized on November 26, 2025. Refunds and credits of shares to demat accounts will happen on November 27. The company is set to list on both NSE and BSE on November 28, 2025.
Anchor investors showed strong participation, raising ₹268.50 crore at the issue price on November 20. For investors seeking exposure to the specialty pharma ingredients sector with established certifications and global clients, today is the final opportunity to apply for the offering.
